{
  "$schema": "folio-library-entry/v1",
  "id": "10665-249154",
  "blocks": [
    {
      "id": "library/10665-249154/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 13,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "The use of loop-mediated isothermal  \namplification (TB-LAMP)  \nfor the diagnosis of pulmonary tuberculosis \nPOLICY GUIDANCE\nEARLY DIAGNOSIS\nLOOP-MEDIATED ISOTHERMAL \nAMPLIFICATION\nDNA\nTUBERCULOSIS\nTB-LAMP\nNEW DIAGNOSTIC TEST\nMOLECULAR DIAGNOSTICS\nPULMONARY TB\nRECOMMENDATIONS\nDIAGNOSIS\nMOLECULAR DIAGNOSTICS\nRAPID MOLECULAR TEST\nM. TUBERCULOSIS \nCOMPLEX\nTHE\nSTRATEGY\nEND TB\nThe use of loop-mediated isothermal \namplification (TB-LAMP) for the \ndiagnosis of pulmonary tuberculosis \nPolicy guidance\nWHO Library Cataloguing-in-Publication Data\nThe use of loop-mediated isothermal amplification (TB-LAMP",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO policy guidance on using loop-mediated isothermal amplification (TB-LAMP) to diagnose pulmonary tuberculosis. It includes the cover, cataloguing data with ISBN, copyright and disclaimer notices, and a table of contents covering methods, results of the systematic review, cost-effectiveness and recommendations. It also contains acknowledgements and lists of contributors. It ends with the declarations of interest of Guideline Development Group members and the planned review date of 2020.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 13,
      "pageEnd": 15,
      "target": "../sections/sec-000-executive-summary.md",
      "narrative": null,
      "content": "Executive summary\nBackground\nWorld Health Organization’s (WHO’s) End TB Strategy calls for the early diagnosis of tuberculosis \n(TB) and for universal drug-susceptibility testing, highlighting the critical role of laboratories in the \npost-2015 era in rapidly and accurately detecting TB and drug resistance.1 Molecular assays based \non nucleic acid amplification techniques, such as polymerase chain reaction, have been developed \nfor rapid TB diagnosis and are being implemented in developing countries. Loop-mediated \nisothermal amplification (LAMP) is a unique, temperature-independent technique",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the TB-LAMP policy guidance, explaining the End TB Strategy's call for early diagnosis and how the manual LAMP assay works and can be read under ultraviolet light. It recounts the 2012 Guideline Development Group review and the newer evidence assessment. It then states the conditional recommendations for using TB-LAMP instead of, or after, sputum-smear microscopy, together with remarks limiting their scope.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 15,
      "pageEnd": 19,
      "target": "../sections/sec-001-1-background.md",
      "narrative": null,
      "content": "Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and \ncontrol include improving case-detection and detecting patients earlier, particularly patients with \nsmear-negative TB disease. In 2014, only 63% (6 million) of an estimated 9.6 million people who \ndeveloped TB were reported to WHO, meaning that globally 37% of the estimated cases of TB \nare undetected. WHO has identified the development and evaluation of new diagnostic tools as a \nnecessary part of further efforts.3\nWHO’s End TB Strategy calls for the early diagnosis of TB and for universal d",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the background to TB-LAMP, noting that a large share of TB cases worldwide go undetected and that new diagnostics are a priority. It describes the commercial Eiken assay, its modest infrastructure needs and its history of WHO review. It then walks through the TB-LAMP workflow, from sample preparation and heating to visual reading of fluorescence and waste disposal.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p016-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../images/img-p016-1.webp",
      "narrative": "draft",
      "content": "Schematic diagram of the molecular principles of TB-LAMP (Figure 1): coloured DNA strands with primer-binding regions labelled F1, F2, F1c, F2c, B1, B2, B1c and B2c pass through numbered stages (8)–(11) linked by arrows in a cycle. Loop (dumbbell and hairpin) structures form at the strand ends and are elongated into long zigzag products made of alternately inverted repeats of the target sequence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p017-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../images/img-p017-1.webp",
      "narrative": "draft",
      "content": "Photograph of a strip of eight reaction tubes under ultraviolet light (Figure 2): the four tubes on the left are clear, while the four on the right show bright green fluorescence at the bottom, illustrating negative and positive TB-LAMP results.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p018-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../images/img-p018-1.webp",
      "narrative": "draft",
      "content": "Workflow diagram of TB-LAMP made of photographs joined by arrows (Figure 3). Steps: collect 60 µl from the sputum cup using an Eiken disposable pipette into a heating tube; heat on a heating block at 90 °C for 5 min; attach and shake the adsorbent tube; fit the injection cap; add 30–35 µl (between lines) to reaction tubes containing dried reagents; close lids and let stand upside down for 2 min; mix; run the LAMP reaction at 67 °C for 40 min; and detect the fluorescent signal.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-002-2-methods.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evidence synthesis",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-003-21-evidence-synthesis.md",
      "narrative": null,
      "content": "In accordance with WHO’s standards for assessing evidence when formulating policy \nrecommendations, the GRADE approach (Grading of Recommendations Assessment, Development \nand Evaluation, see http://www.gradeworkinggroup.org/) was used. GRADE provides a structured \nframework for evaluating the accuracy of diagnostic tests and their impact on patients and public \nhealth. \nThe evaluation used the GRADE system to determine the quality of the evidence and provide \ninformation on the strength of the recommendations using PICO questions agreed by the GDG. \nPICO refers to the following four elements",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the GRADE approach and PICO-framed questions were used to assess the evidence on TB-LAMP. It lists the four review questions on accuracy versus microscopy, use as an add-on test, comparison with Xpert MTB/RIF, and rates of invalid results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Criteria for considering studies for this review",
      "pageStart": 19,
      "pageEnd": 21,
      "target": "../sections/sec-004-22-criteria-for-considering-studies-for-this-rev.md",
      "narrative": null,
      "content": "The review included all prospective studies that evaluated the use of TB-LAMP on sputum samples \nfrom adults with signs and symptoms consistent with pulmonary TB that were conducted in \nsettings with an intermediate or high burden of TB. All included studies were conducted after 1 \nJanuary 2012, using the final, design-locked TB-LAMP protocol that had been modified by the \nmanufacturer. Twenty studies were identified, including all studies that were directly conducted by \nFIND (the Foundation for Innovative New Diagnostics) or funded through FIND following a request \nfor applications (RFAs). T",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines which TB-LAMP studies were eligible for the systematic review, including prospective studies after 2012 in intermediate- and high-burden settings and a supplementary literature search. It lists exclusion criteria for studies and individual participants and describes the culture-based reference standards and smear microscopy definitions used.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Data collection and analysis",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-005-23-data-collection-and-analysis.md",
      "narrative": null,
      "content": "For studies conducted by or funded through FIND, study protocols, inclusion criteria and definitions \nwere provided by FIND along with data on individual participants. Further review of the individual-\nlevel data was performed to verify that the study and individual participants met eligibility criteria. \nFor studies not affiliated with FIND, individual-level data were requested from the investigators and \nreviewed by at least two authors to determine whether data met the criteria for inclusion in the \nreview.\nFor each study, the minimum data required for each individual enrolled were:\n•  Age",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how individual-level data were obtained from FIND-affiliated and other TB-LAMP studies, listing the minimum and optional variables collected. It then outlines how accuracy, incremental yield and invalid result rates were calculated and how heterogeneity was assessed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline Development Group meeting",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-006-24-guideline-development-group-meeting.md",
      "narrative": null,
      "content": "Following the initial GDG meeting on TB-LAMP in 2012, a GDG meeting was convened by WHO \nin January 2016 to review the evidence from 20 new studies, of which 13 studies conducted \nin 11 countries met the inclusion criteria. The guideline methodologist participated in the initial \nplanning and scoping and in the development of the key questions for the GDG meeting but did \nnot participate in the meeting.\nThe WHO Steering Group was responsible for scoping the guideline, drafting the PICO questions \nand overseeing evidence retrieval and analyses. The Steering Group was also responsible for",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that a WHO Guideline Development Group met in January 2016 to review 20 new TB-LAMP studies, 13 of which met inclusion criteria, and outlines the roles of the methodologist and Steering Group.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "External Review Group",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-007-25-external-review-group.md",
      "narrative": null,
      "content": "Interest and for organizing the GDG meetings. A brief biography of each GDG member was made \navailable for public scrutiny on the website of the WHO Global TB Programme (http://www.who.\nint/tb/areas-of-work/laboratory/policy_statements/en/) 2 weeks prior to the GDG meeting. PICO \nquestions were drafted by the Steering Group and were presented to the GDG for discussion \nand modification. The Steering Group also prepared an initial list of relevant outcomes, including \ndesirable effects and undesirable effects, and requested the GDG to identify any other important \noutcomes. \nDuring the meeting,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how the Steering Group handled interests, PICO questions and the consensus process for the TB-LAMP recommendations, and how an External Review Group of laboratory experts found no major errors or concerns in the guidance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Scope",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-008-3-scope.md",
      "narrative": null,
      "content": "3. Scope\nThis document provides a pragmatic summary of the evidence and recommendations on using \nTB-LAMP to diagnose pulmonary TB in adults with signs and symptoms consistent with TB. It \nshould be read in conjunction with the WHO’s 2015 framework for implementing TB diagnostics, \nwhich provides guidance on implementing the diagnostic tools and methods approved by WHO \nwithin the context of a country’s infrastructure, resources, epidemiology and in the presence of \ndrug-resistant TB and HIV.9 http://www.who.int/tb/publications/implementing_TB_diagnostics/en/",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that the guidance summarizes evidence and recommendations on using TB-LAMP for pulmonary TB in symptomatic adults and should be read with WHO's 2015 framework for implementing TB diagnostics.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target audience",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-009-31-target-audience.md",
      "narrative": null,
      "content": "This guidance is intended to be used by clinicians treating patients with TB, and managers and \nlaboratory directors working in TB programmes, in coordination with external laboratory consultants, \ndonor agencies, technical advisers, laboratory technicians, procurement officers for laboratory \nequipment, service providers in the private sector, relevant government sectors, and implementation \npartners that are involved in country-level strengthening of TB diagnostic and treatment services. \nIndividuals responsible for programme planning, budgeting, mobilizing resources and implementing \ntraini",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies the intended users of the TB-LAMP guidance, from clinicians and laboratory directors to donors, procurement officers and programme planners.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evidence base for policy formulation",
      "pageStart": 24,
      "pageEnd": 27,
      "target": "../sections/sec-010-4-evidence-base-for-policy-formulation.md",
      "narrative": null,
      "content": "Of the 20 studies identified that evaluated TB-LAMP, 13 studies conducted in 11 countries met \nthe criteria for inclusion in the systematic review (Fig. 4). Six studies were excluded because it was \nunclear whether participants had been receiving TB treatment within 60 days prior to enrolment. \nOne study was excluded because rapid speciation testing on positive mycobacterial cultures was \nnot performed. (Annex 1 comprises references to the studies identified for the systematic review of \nthe diagnostic accuracy of TB-LAMP.)\nOf the 20 studies identified as evaluating TB-LAMP, 10 had not been pu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the evidence base for the TB-LAMP recommendations: of 20 studies identified, 13 in 11 countries met inclusion criteria, many of them unpublished. It explains the role of FIND in conducting or sponsoring most studies and gives participant numbers and study periods. Tables summarize study characteristics such as setting, HIV prevalence and reference standards.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/figure-vfig-p025",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../figures/vfig-p025.webp",
      "narrative": "draft",
      "content": "Flow diagram of TB-LAMP studies (Figure 4): 20 studies identified; 7 excluded (in 6, patients treated for TB within 60 days of enrolment were not excluded; in 1, MTBC speciation was not performed); 13 studies included. These comprise 4 evaluation studies (Brazil, Peru, South Africa, Viet Nam), 1 demonstration study (India), 7 RFA studies (Côte d'Ivoire, India, Madagascar, Malawi, Uganda, United Republic of Tanzania, Viet Nam) and 1 unpublished study (Haiti).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Characteristics for all studies included in the evaluation of TB-LAMP (see Annex 1 for information about the studies)",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table describes the 13 studies included in the evaluation of TB-LAMP, by country and study type. For each study it gives the health system level, microscopy and culture methods, MGIT contamination rate, tests done on stored sputum, Xpert MTB/RIF specimen type, participants’ median age, the percentages female and HIV-negative, and the percentages with culture-positive and smear-negative TB.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Assessment of methodological quality",
      "pageStart": 27,
      "pageEnd": 29,
      "target": "../sections/sec-011-41-assessment-of-methodological-quality.md",
      "narrative": null,
      "content": "The quality of the included studies was appraised with the Quality Assessment of Diagnostic \nAccuracy Studies (QUADAS-2) tool.10 QUADAS-2 consists of four domains: patient selection, index \ntest, reference standard, and flow and timing. All domains were assessed for the potential for risk \nof bias, and the first three domains for concerns regarding applicability. Signalling questions in \neach domain were used to form judgements about the risk of bias. Overall, the risk of bias was \nconsidered to be high because of problems with the culture-based reference standard (all studies), \nunclear patie",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports the QUADAS-2 appraisal of the included TB-LAMP studies, judging overall risk of bias as high mainly because of the culture reference standard, unclear patient selection and flow and timing problems. A table gives each study's risk-of-bias and applicability ratings, and notes explain the judgements.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Risk of bias and applicability concerns: review authors’ judgements about each domain (see Annex 1 for information about the studies)",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table gives the review authors’ QUADAS-2 judgements (low, high or unclear) for each of the 13 TB-LAMP studies: risk of bias in four domains (patient selection, index test, reference standard, flow and timing) and applicability concerns in three domains.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Results of the systematic review",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/sec-012-5-results-of-the-systematic-review.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Accuracy of TB-LAMP as a replacement test for smear microscopy",
      "pageStart": 29,
      "pageEnd": 31,
      "target": "../sections/sec-013-51-accuracy-of-tb-lamp-as-a-replacement-test-for.md",
      "narrative": null,
      "content": "Of the 4 760 adults eligible for inclusion in the analysis, 1 810 participants (38%) across 7 studies \nqualified for Standard 1 status; 3 110 participants (65%) across 10 studies qualified for Standard 2; \nand 4 596 participants (97%) across 13 qualified for Standard 3 (Table 3). \nTable 3. TB-LAMP as a replacement test for smear microscopy: eligible and included \npatients, by reference standard and study site (see Annex 1 for information about  \nthe studies)\nStudy\nTotal \nnumber of \nparticipants\nNumber of \nparticipants \neligiblea\nNumber (%) includedb\nStandard 1\nStandard 2\nStandard 3\nBrazil (EVA",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the accuracy of TB-LAMP as a replacement for smear microscopy, with the numbers of eligible and included participants by study and reference standard. Forest plots and pooled sensitivity and specificity estimates are given for each of the three culture-based standards. Table notes define the standards used.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3. TB-LAMP as a replacement test for smear microscopy: eligible and included patients, by reference standard and study site (see Annex 1 for information about the studies)",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "For the analysis of TB-LAMP as a replacement for smear microscopy, the table gives for each of the 13 study sites the total number of participants, the number eligible and the number (%) included under each of three culture-based reference standards, with totals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p030-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../images/img-p030-1.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals for detecting TB against culture reference Standard 1 (Figure 5), with TP, FP, FN and TN counts for seven studies (Brazil, Peru, South Africa and Vietnam evaluation studies; Uganda and Madagascar RFA; Haiti unpublished). Sensitivity ranges from 0.66 (Uganda) to 0.91 (Peru), while specificity is 0.90–0.99.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p030-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../images/img-p030-2.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals against culture reference Standard 2 (Figure 5), with TP, FP, FN and TN counts for ten studies, adding India (Demo), Malawi (RFA) and Tanzania (RFA) to those in Standard 1. Sensitivity ranges from 0.62 (Malawi) to 0.91 (Peru), while specificity is 0.90–1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p030-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../images/img-p030-3.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals against culture reference Standard 3 (Figure 5), with TP, FP, FN and TN counts for 13 studies, including India (RFA), Vietnam (RFA) and Ivory Coast (RFA). Sensitivity ranges widely from 0.48 (Vietnam RFA) to 1.00 (India RFA), while specificity stays between 0.90 and 1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p031-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../images/img-p031-1.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals among adults living with HIV against culture reference Standard 1 (Figure 6), for two studies: South Africa (Eval), sensitivity 0.54 and specificity 1.00, and Uganda (RFA), sensitivity 0.58 and specificity 0.98.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p031-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../images/img-p031-2.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals among adults living with HIV against culture reference Standard 2 (Figure 6), for four studies (South Africa, Malawi, Tanzania, Uganda). Sensitivity ranges from 0.54 to 0.82 (Tanzania) and specificity from 0.75 (Tanzania, with a wide interval) to 1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p031-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../images/img-p031-3.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals among adults living with HIV against culture reference Standard 3 (Figure 6), for five studies (South Africa, Malawi, Tanzania, Uganda, Ivory Coast). Sensitivity ranges from 0.54 to 0.96 (Ivory Coast) and specificity from 0.33 (Ivory Coast) to 1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-vfig-p031",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../figures/vfig-p031.webp",
      "narrative": "draft",
      "content": "Render of a report page showing the end of Table 4 (pooled sensitivity 77.7%, 76.0% and 80.3% and pooled specificity 98.1%, 98.0% and 97.7% for reference Standards 1–3) followed by Figure 6: forest plots of TB-LAMP sensitivity and specificity among adults living with HIV against Standards 1, 2 and 3, with two, four and five studies respectively. Individual-study sensitivity ranges from 0.54 to 0.96 and specificity from 0.33 to 1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Accuracy of TB-LAMP as a replacement test for smear microscopy in persons living with HIV",
      "pageStart": 31,
      "pageEnd": 32,
      "target": "../sections/sec-014-52-accuracy-of-tb-lamp-as-a-replacement-test-for.md",
      "narrative": null,
      "content": "with HIV\nMost studies did not collect data on HIV status and most patients had unknown HIV status at the time \nof enrolment. Of the 385 adults with known HIV infection who were eligible for inclusion in the analysis, \n169 participants (44%) in 2 studies qualified for Standard 1 status; 271 (70%) across 4 studies qualified \nfor Standard 2; and 370 (96%) across 5 studies qualified for Standard 3. For Standard 1, the sensitivity \nof TB-LAMP in individual studies ranged from 54% to 58%; for Standard 2, the range was 54–82%; \nand for Standard 3, the range was 54–96% (Fig. 6). The corresponding rang",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports the limited data on TB-LAMP accuracy among adults living with HIV, giving the ranges of sensitivity and specificity across studies for each reference standard. It notes greater heterogeneity and provides pooled estimates in a table.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4. TB-LAMP as a replacement test for smear microscopy: estimates of pooled sensitivity and specificity",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../tables/table-4.csv",
      "narrative": "draft",
      "content": "The table gives the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP used as a replacement test for smear microscopy against each of three culture-based reference standards.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Accuracy of TB-LAMP as an add-on test following smear microscopy for smear-negative adults",
      "pageStart": 32,
      "pageEnd": 34,
      "target": "../sections/sec-015-53-accuracy-of-tb-lamp-as-an-add-on-test-followi.md",
      "narrative": null,
      "content": "adults\nThe diagnostic accuracy of TB-LAMP for detecting smear-negative culture-confirmed pulmonary \nTB was limited to adult participants with two negative sputum-smear microscopy results. Of 2 972 \nparticipants eligible for the analysis, 1 349 (45%) across 7 studies qualified for Standard 1 status; \n2 190 (74%) across 9 studies qualified for Standard 2; and 2 916 (98%) across 11 studies qualified \nfor Standard 3 (Table 6).\nTable 6. TB-LAMP as an add-on test following negative sputum-smear microscopy: \neligible and included patients, by reference standard and study site (see Annex 1 \nfor inform",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the accuracy of TB-LAMP as an add-on test for adults with two negative smear results, with participant numbers by study and reference standard. Pooled sensitivity and specificity for smear-negative, culture-positive TB are shown with forest plots. Table notes define the culture standards.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5. TB-LAMP as a replacement test for smear microscopy in persons living with HIV: pooled sensitivity and specificity",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../tables/table-5.csv",
      "narrative": "draft",
      "content": "The table gives the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP used as a replacement test for smear microscopy in persons living with HIV (not estimated for Standard 1 because fewer than 4 studies were eligible) against each of three culture-based reference standards.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/table-006",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6. TB-LAMP as an add-on test following negative sputum-smear microscopy: eligible and included patients, by reference standard and study site (see Annex 1 for information about the studies)",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../tables/table-6.csv",
      "narrative": "draft",
      "content": "For the analysis of TB-LAMP as an add-on test after negative sputum-smear microscopy, the table gives for each of the 13 study sites the total number of participants, the number eligible and the number (%) included under each of three culture-based reference standards, with totals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p033-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../images/img-p033-1.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals as an add-on test following negative sputum-smear microscopy, against culture reference Standard 1 (Figure 7), for seven studies. Sensitivity is low and variable, from 0.19 (Haiti) to 0.78 (Peru), while specificity is 0.90–1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p033-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../images/img-p033-2.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals as an add-on test following negative sputum-smear microscopy, against culture reference Standard 2 (Figure 7), for nine studies. Sensitivity ranges from 0.17 (Tanzania) to 0.81 (India Demo), while specificity is 0.90–1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p034-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../images/img-p034-1.webp",
      "narrative": "draft",
      "content": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals as an add-on test following negative sputum-smear microscopy, against culture reference Standard 3 (Figure 7, continued), for 11 studies. Sensitivity ranges from 0.17 (Tanzania) to 0.81 (India Demo), while specificity is 0.90–1.00.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Accuracy of TB-LAMP compared with Xpert MTB/RIF assay for detecting pulmonary TB",
      "pageStart": 34,
      "pageEnd": 36,
      "target": "../sections/sec-016-54-accuracy-of-tb-lamp-compared-with-xpert-mtbri.md",
      "narrative": null,
      "content": "The difference in diagnostic accuracy between TB-LAMP and the Xpert MTB/RIF assay for \ndetecting pulmonary TB compared with culture as the reference standard was determined for \nparticipants who underwent both TB-LAMP and Xpert MTB/RIF testing on non-frozen specimens. \nOf 2 837 participants eligible for inclusion in the analysis, 1 075 (38%) across four studies qualified \nfor Standard 1 status; 1 809 (64%) across 6 studies qualified for Standard 2; and 2 772 (98%) \nacross eight studies qualified for Standard 3 (Table 8).\nTable 8. Diagnostic accuracy of TB-LAMP compared with the Xpert MTB/RIF a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Compares the diagnostic accuracy of TB-LAMP and the Xpert MTB/RIF assay in participants tested with both, giving numbers of included participants by study. Pooled sensitivity and specificity for each test and their differences are presented across three reference standards.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/table-007",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7. TB-LAMP as an add-on test following smear microscopy: pooled sensitivity and specificity",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../tables/table-7.csv",
      "narrative": "draft",
      "content": "The table gives the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP used as an add-on test following smear microscopy against each of three culture-based reference standards.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/table-008",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 8. Diagnostic accuracy of TB-LAMP compared with the Xpert MTB/RIF assay: eligible and included patients, by reference standard and study site. (See Annex 1 for information about the studies)",
      "pageStart": 35,
      "pageEnd": 35,
      "target": "../tables/table-8.csv",
      "narrative": "draft",
      "content": "For the comparison of TB-LAMP with the Xpert MTB/RIF assay, the table gives for each of the 13 study sites the total number of participants, the number eligible and the number (%) included under each of three culture-based reference standards, with totals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB-LAMP is used to detect pulmonary TB among all adults and among HIV-positive adults",
      "pageStart": 36,
      "pageEnd": 37,
      "target": "../sections/sec-017-tb-lamp-is-used-to-detect-pulmonary-tb-among-all.md",
      "narrative": null,
      "content": "to detect pulmonary TB among all adults and among HIV-positive adults\nAll 4 760 patients eligible for the analysis of the accuracy of TB-LAMP among adults were included \nin the analysis to determine the proportion of indeterminate or invalid TB-LAMP results (Table 3). \nThe proportion of indeterminate TB-LAMP results was 0% in 11 studies and 1% in 2 studies. \nThere was minimal heterogeneity across studies (I2: 28%; P = 0.25). The pooled proportion of \nindeterminate TB-LAMP results was 0% (95% CI: 0–0). Results were similar among HIV-positive \nadults; the pooled proportion of indeterminate TB-LA",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that indeterminate or invalid TB-LAMP results were rare, with a pooled proportion of about zero among all adults and among those with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/table-009",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 9. Accuracy of TB-LAMP and the Xpert MTB/RIF assay: pooled sensitivity and specificity",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../tables/table-9.csv",
      "narrative": "draft",
      "content": "The table compares the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP and the Xpert MTB/RIF assay against each of three culture-based reference standards, among participants with valid results for both tests on non-frozen specimens.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cost-effectiveness analysis",
      "pageStart": 37,
      "pageEnd": 38,
      "target": "../sections/sec-018-6-cost-effectiveness-analysis.md",
      "narrative": null,
      "content": "6. Cost-effectiveness analysis\nThis analysis provides evidence for the cost–effectiveness of TB-LAMP as a replacement test for \nsputum-smear microscopy or as an add-on test to sputum-smear microscopy in the further testing \nof smear-negative patients compared with the standard of care in settings where coverage of the \nXpert MTB/RIF assay is limited (H. Sohn, Cost, affordability, and cost-effectiveness of TB-LAMP \nassay: report to WHO Guideline Development Group meeting on the TB-LAMP assay, unpublished \nreport, January 2016).\nFor the cost analysis, a bottom-up micro-costing analysis was condu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes a costing study of TB-LAMP and Xpert MTB/RIF in peripheral laboratories in Malawi and Viet Nam, comparing TB-LAMP strategies with microscopy-based care. It gives per-test costs and affordability and cost-effectiveness findings, and cautions policy-makers to weigh feasibility and costs before adoption.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary: from evidence to recommendations",
      "pageStart": 38,
      "pageEnd": 38,
      "target": "../sections/sec-019-7-summary-from-evidence-to-recommendations.md",
      "narrative": null,
      "content": "The accuracy of TB-LAMP performed directly on sputum samples for diagnosing pulmonary TB \namong adults who have not received TB treatment within 60 days of enrolment was determined \nfrom 13 studies performed in countries with intermediate and high burdens of TB.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the evidence-to-recommendation summary, noting that TB-LAMP accuracy on sputum was determined from 13 studies in intermediate- and high-burden countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB-LAMP for the detection of pulmonary TB in all adults",
      "pageStart": 38,
      "pageEnd": 38,
      "target": "../sections/sec-020-71-tb-lamp-for-the-detection-of-pulmonary-tb-in.md",
      "narrative": null,
      "content": "Using data from the 1 810 persons with signs and symptoms consistent with TB for whom the most \nstringent reference standard could be used (Standard 1), TB-LAMP had a pooled sensitivity that \nwas 15% higher than smear microscopy (78% compared with 63%). Although pooled specificity \nestimates for TB-LAMP were 2% lower (98% compared with 100%), this may be partly explained \nby the identification of TB cases who were misclassified as TB-negative by the use of culture as a \nreference standard, which varied across studies. All included studies were considered to have a high \nrisk of bias in the use",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the Guideline Development Group's reasoning on TB-LAMP for all adults: higher sensitivity than microscopy with slightly lower specificity, partly attributed to culture misclassification. It weighs the extra cases detected per 1 000 tested against false positives and concludes the trade-off is acceptable.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB-LAMP for the detection of pulmonary TB in adults living with HIV",
      "pageStart": 38,
      "pageEnd": 39,
      "target": "../sections/sec-021-72-tb-lamp-for-the-detection-of-pulmonary-tb-in.md",
      "narrative": null,
      "content": "Data from 4 studies (271 participants) that included HIV-positive adults with signs and symptoms \nconsistent with pulmonary TB and that evaluated the accuracy of TB-LAMP demonstrated \nsensitivity and specificity similar to sputum-smear microscopy (sensitivity: 64% for TB-LAMP and \n62% for smear microscopy; specificity: 99% for TB-LAMP and 99% for smear microscopy)(Annex \n2, Table 11). Based on this limited dataset, similar numbers of true-positive, false-negative, false-\npositive and true-negative results would be obtained using either TB-LAMP or sputum-smear \nmicroscopy. Although it would be",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that in a small HIV-positive group TB-LAMP performed about the same as smear microscopy, and explains why the group made no specific recommendation for people living with HIV, citing limited evidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB-LAMP as an add-on test for detecting of pulmonary TB in adults following negative smear microscopy",
      "pageStart": 39,
      "pageEnd": 39,
      "target": "../sections/sec-022-73-tb-lamp-as-an-add-on-test-for-detecting-of-pu.md",
      "narrative": null,
      "content": "smear microscopy \nUsing data from the 1 349 persons with signs and symptoms consistent with TB in the 7 studies \nto which the most stringent reference standard could be applied (Standard 1), TB-LAMP showed \na 42% incremental yield in patients with culture-confirmed TB who had a negative sputum-smear \nmicroscopy result. Pooled specificity estimates for TB-LAMP were 2% lower (98% versus 100% \nfor smear microscopy), and this may be partly explained by the identification of TB cases that were \nmisclassified as TB-negative using culture as a reference standard, which varied across studies. \nAll inc",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the reasoning for TB-LAMP as an add-on test after negative smear microscopy, citing a 42% incremental yield and slightly lower specificity. It concludes that more cases would be found with an acceptable number of false positives.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB-LAMP as a replacement test for the Xpert MTB/RIF assay for detecting pulmonary TB in adults",
      "pageStart": 39,
      "pageEnd": 41,
      "target": "../sections/sec-023-74-tb-lamp-as-a-replacement-test-for-the-xpert-m.md",
      "narrative": null,
      "content": "TB in adults\nAlthough better than microscopy, the pooled sensitivity of TB-LAMP is lower than what has been \nreported for the Xpert MTB/RIF assay (89%; 95% credible interval: 85–92).11 The specificity of all \nthree tests is similar. In head-to-head comparisons, TB-LAMP appeared to be less sensitive than \nthe Xpert MTB/RIF assay, but the difference in sensitivity was not statistically significant except \nwhen using the least stringent reference standard. More data are needed to confirm that TB-LAMP \nsensitivity is lower than that of the Xpert MTB/RIF assay. It is also important to consider that",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Compares TB-LAMP with Xpert MTB/RIF, noting lower sensitivity and no rifampicin resistance detection, and explains why Xpert remains preferred where resources allow while TB-LAMP may suit peripheral sites.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHO policy recommendations",
      "pageStart": 41,
      "pageEnd": 42,
      "target": "../sections/sec-024-8-who-policy-recommendations.md",
      "narrative": null,
      "content": "8. WHO policy recommendations\nGiven the GRADE evidence assessment and considering the relative benefits and harms associated \nwith the use of the TB-LAMP, WHO recommends the following.\n1.  \u0007TB-LAMP may be used as a replacement test for sputum-smear microscopy to diagnose \npulmonary TB in adults with signs and symptoms consistent with TB (conditional \nrecommendation, very low-quality evidence).\n2.  \u0007TB-LAMP may be used as a follow-on test to smear microscopy in adults with signs and \nsymptoms consistent with pulmonary TB, especially when further testing of sputum smear-\nnegative specimens is ne",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States WHO's two conditional recommendations, based on very low-quality evidence, for TB-LAMP as a replacement for or follow-on to smear microscopy in symptomatic adults. Remarks restrict their use to sputum, caution against replacing rapid rifampicin-resistance tests and note uncertainty for people with HIV and extrapolation to children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implementation considerations",
      "pageStart": 42,
      "pageEnd": 43,
      "target": "../sections/sec-025-9-implementation-considerations.md",
      "narrative": null,
      "content": "9. Implementation considerations\nThe systematic review supports the use of TB-LAMP as a replacement test for smear microscopy \nfor diagnosing pulmonary TB in countries with an intermediate or high burden of TB. However, the \nXpert MTB/RIF assay should remain the preferred diagnostic for all persons suspected of having \nTB, providing there are sufficient resources and infrastructure to support its use, given the evidence, \nits ability to simultaneously identify rifampicin resistance and because it is automated.\n•  \u0007Several operational issues accompany the implementation of TB-LAMP: the needs fo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists implementation considerations for TB-LAMP, including electricity, storage temperature, waste disposal and stock needs. It also notes that smear microscopy is still needed for treatment monitoring and that Xpert MTB/RIF should not be replaced.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Plans for disseminating WHO’s guidance on TB-LAMP",
      "pageStart": 43,
      "pageEnd": 44,
      "target": "../sections/sec-026-10-plans-for-disseminating-whos-guidance-on-tb-l.md",
      "narrative": null,
      "content": "10. Plans for disseminating WHO’s guidance on TB-LAMP \nThis WHO guidance will be published online (http://www.who.int/tb/publications/lamp-diagnosis-\nmolecular/en/) and disseminated through WHO’s Global TB Department listserv to all WHO Regional \nand Country Offices and Member States, the Global Laboratory Initiative, the New Diagnostics \nWorking Group of the Stop TB Partnership, and donors, technical agencies and other stakeholders.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how the TB-LAMP guidance will be published online and distributed to WHO offices, Member States and partner networks.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Research needs",
      "pageStart": 44,
      "pageEnd": 45,
      "target": "../sections/sec-027-11-research-needs.md",
      "narrative": null,
      "content": "11. Research needs \nThe current recommendations for the commercial TB-LAMP manual assay should not prevent or \nrestrict further research on new TB diagnostics, especially point-of-care assays that can be used \nas close as possible to where patients access TB treatment. Additional studies using standardized \nprotocols that include a high-quality culture reference standard (liquid culture results on at least \ntwo samples) are needed to better inform national TB programmes of the relative performance of \nTB-LAMP compared with the the Xpert MTB/RIF assay. Further operational research on TB-LAMP \ns",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists research needs for TB-LAMP, such as studies with stronger culture reference standards, evaluation of diagnostic algorithms, training needs, patient impact and country-specific cost analyses.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexes",
      "pageStart": 45,
      "pageEnd": 45,
      "target": "../sections/sec-028-12-annexes.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References to studies for the systematic review of the diagnostic accuracy of TB-LAMP",
      "pageStart": 45,
      "pageEnd": 47,
      "target": "../sections/sec-029-annex-1-references-to-studies-for-the-systematic.md",
      "narrative": null,
      "content": "TB-LAMP \nStudies included in the review\n1.\t\n\u0007Hang PT, Peter J, Mello FCQ, Parraga T, Nguyen TNL, Nabeta P, et al. Performance of the \nTB-LAMP diagnostic assay in reference laboratories – results from a multi-centre study (Brazil, \nPeru, South Africa, Vietnam). Submitted to the International Journal of Tuberculosis and Lung \nDisease, April 2016.\n2.\t\n\u0007Gray CM, Katamba A, Narang P, Giraldo J, Zamudio C, Joloba M, et al. Feasibility and \noperational performance of TB LAMP in decentralized settings – results from a multi-centre \nstudy. Submitted to the Journal of Clinical Microbiology, April 2016.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A reference list of the studies included in, and excluded from, the systematic review of TB-LAMP diagnostic accuracy, many unpublished or submitted for publication.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "GRADE Evidence Profiles",
      "pageStart": 47,
      "pageEnd": 50,
      "target": "../sections/sec-030-annex-2-grade-evidence-profiles.md",
      "narrative": null,
      "content": "Table 10. GRADE evidence profile: accuracy of TB-LAMP as a replacement test for sputum-smear microscopy for diagnosing \npulmonary TB among all adults suspected of having pulmonary TB \nQuestion: What is the diagnostic accuracy of TB-LAMP for to diagnose \npulmonary tuberculosis in all adults with presumptive pulmonary TB compared \nwith a culture reference standard?\nParticipants: Adult patients suspected of having TB\nPrior testing: None\nRole: Replacement test for sputum smear microscopy\nSettings: Peripheral level laboratories\nIndex (new) test: TB-LAMP \nReference standard: Culture (Reference stand",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents GRADE evidence profiles comparing TB-LAMP with sputum-smear microscopy for diagnosing pulmonary TB in adults, against a culture reference standard. Tables give pooled sensitivity and specificity and the expected true and false positives and negatives per 1000 patients at different pre-test probabilities. Footnotes explain why the evidence was rated very low or low quality, citing risk of bias, indirectness and heterogeneity across studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abstracts for unpublished studies",
      "pageStart": 50,
      "pageEnd": 52,
      "target": "../sections/sec-031-annex-3-abstracts-for-unpublished-studies.md",
      "narrative": null,
      "content": "Included study 4. Comparison of pulmonary tuberculosis diagnosis by AFB detection, \nTB-LAMP and GeneXpert MTB/RIF in Ivory Coast\nK. N’guessan,1 K. Horo2, I. Coulibaly,3 J. Adegbele,1 N. Kouame-Adjei,3 H. Seck-Angu,1 A. Guei,1 \nJ. Kouakou,4 M. Dosso1\n1 Laboratoire Nationale de Référence de la Tuberculose, Institut Pasteur de Côte d’Ivoire, 01BP 490 Abidjan 01 \n2 Service de Pneumologie CHU de Cocody\n3 Centre Antituberculeux de Yopougon\n4 Programme National de Lutte contre la Tuberculose.\nBackground: The specificity of acid-fast microscopy is excellent for mycobacterial species, but \nits sensitiv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reproduces abstracts of unpublished studies on TB-LAMP included in the review, beginning with a Côte d'Ivoire study comparing smear microscopy, TB-LAMP and GeneXpert MTB/RIF against liquid culture in symptomatic patients. Each abstract outlines background, methods, sample sizes and the sensitivity and specificity results obtained. The section ends with WHO Global TB Programme contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-249154/blocks/figure-img-p052-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 52,
      "pageEnd": 52,
      "target": "../images/img-p052-1.webp",
      "narrative": "draft",
      "content": "An ISBN barcode with the number 9 789241 511186 printed beneath it.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
